Genomics Ltd. Extends Drug Discovery Collaboration with Vertex Pharmaceuticals
Genomics Ltd. has announced a four-year extension of its strategic collaboration with Vertex Pharmaceuticals, building upon an existing partnership that began in 2018. The agreement focuses on leveraging large-scale human genetic data and proprietary algorithms to discover and validate novel drug targets and biomarkers for precision medicines. The extended deal carries a total potential value exceeding $220 million, contingent upon the achievement of specific research, development, regulatory, and commercial milestones. Additionally, Genomics is entitled to tiered royalties on future net sales of any products resulting from the collaboration. This partnership underscores the growing integration of Techbio and human genetics in accelerating drug development for diseases with significant unmet needs.

Tickers: $VRTX
Topics: biotechnology drug discovery human genetics precision medicine